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Abstract. – Probiotics are viable, non-
pathogenic microorganisms (bacteria or yeast)
which when administered in adequate amounts,
confer a health benefit on the host. At this time,
Saccharomyces boulardii is the only yeast com-
monly used in clinical practice. Literature on this
probiotic is wide and even more data become
available each year. Thus, it could be problemat-
ic for a physician summarize all the best infor-
mation deriving from basic research and clinical
studies. With the aim to help physicians in the
use of Saccharomyces boulardii, this paper fo-
cuses on the available evidences for its efficacy
and safety in different diseases in adult and pe-
diatric patients in order to provide a practical
guidance for gastroenterology clinical practice.
Indications and dosage for several gastrointesti-
nal diseases for a correct use of this probiotic
are provided, and recent insights on its mecha-
nisms of action and possible future clinical ap-
plication are also discussed.
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Introduction
Probiotics are viable, non-pathogenic mi-
croorganisms (bacteria or yeast) which when
administered in adequate amounts, confer a
health benefit on the host1. More commonly
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used bacterial probiotics include Lactobacillus
species, Bifidobacterium species, Escherichia
(E.) coli, Streptococcus species, and the yeast
Saccharomyces boulardii (Sb)1-3. With the in-
creasing availability and wide spreading use of
probiotics in gastroenterology clinical practice,
it is important to assess which are the most ef-
fective preparations. A first problem for a
physician could derive from the exact identifica-
tion of the microorganism (strain and concentra-
tion) stated on the label of a particular product.
At this time, Sb is the only yeast commonly
used in clinical practice. The taxonomy of Sac-
charomyces strains has been debated, and in
particular Sb strain has been questioned as to
whether it should be reclassified as a strain of S.
cerevisiae or remain a separate species4. In re-
cent years, due to the availability of metabolom-
ic tools (microsatellite polymorphism analysis
and retrotransposon hybridization analyses), it
has been shown that Sb has a unique clustering
different from other strains of S. cerevisiae5. In
addition, Sb can be distinguished from other
strains of S. cerevisiae by advanced typing
methods, by differences in metabolism and
physiology and by the ability to have anti-mi-
crobial  effects6,7. There are many different Sb
products commercially available, which are sold
either as lyophilized or heat-dried powders in
capsules, or in liquid beverages7. The quality of
these products is variable, and although most
products state they contain at least 1×109
cfu/mg, independent assays have determined
that about 50% of the products contained less7.
In one study comparing six Sb products, all had
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Anti-Microbial Action
Within the intestinal luminal Sb exerts several
anti-microbial activities that could be divided in
two groups:
Direct anti-toxin effects. The anti-toxin action
elicited by Sb is mainly due to small peptides
produced by the yeast. A 54kDa serine pro-
tease is able to inhibit enterotoxin and cyto-
toxic activities of C. difficile by degradation
of toxin A and B and receptors sites of toxin
A on the enterocyte cell surface. Others Sac-
charomyces strains fail to show these activi-
ties10,11. A 120 kDa protein that has a non-
proteolytic activity, competes specifically
with the hyper-secretion caused by the toxins
of Vibrio (V.) cholera decreasing cyclic
adenosine monophosphate in the entero-
cytes12,13. Finally, Sb produces a phosphatase
able to dephosphorylate endotoxins (such as
lipopolysaccharide of E. coli 055B5) and in-
activates its cytotoxic effects14. This mecha-
nism may account for the protection afforded
in cases of sepsis.
Inhibition of growth and invasion of
pathogens. In vitro, Sb directly inhibits the
growth of several pathogens (Candida albi-
cans, E. coli, Shigella, Pseudomonas aerugi-
nosa, Staphylococcus aureus, Entamoeba hys-
tolitica), and cell invasion by Salmonella ty-
phimurium and Yersinia enterocolitica15-17. The
yeast may also act by enhancing the integrity
of the tight junction between enterocytes, thus
preserving intestinal integrity and function18,19.
S. boulardii is also able to reduce the translo-
cation of pathogens in rat and pig animal mod-
els20-22, and it can also interfere with pathogen-
ic attachment to intestinal receptor sites19,23,24.
In enteropathogenic E. coli (EPEC) infection,
Sb acts as a decoy by causing bacterial cells to
directly bind to its surface rather than to ente-
rocytes25. In vitro, Sb inhibits the adhesion of
C.albicans to epithelial cell lines, this effect is
also observed with the extracts of Sb26).A
study suggests the capric acid as factor secret-
ed by Sb and responsible for inhibition of C.
albicans filamentation and partially also adhe-
sion and biofilm formation27. Contrasting data
derives from a recent study in a murine animal
model suggesting that the oral administration
of Sb does not prevent gastrointestinal colo-
nization by C. albicans28. Finally, data on the
effects of Sb against common viruses responsi-
ble for diarrhea (such as Rotavirus, Aden-
identical PCR typing profiles, but only 50% of
them had the same concentration identified on
their label8. Differences in clinical efficacy may
occur due to lower than stated dose but also to
inaccurate strain composition, which may be
due either to probiotic manufacturing technique
(shelf-life), to the specific kind of preparation
or ultimately to the use of probiotic mixture
rather than single strain preparation. All the ran-
domized controlled trials using Sb have utilized
a single strain preparation7. Although mixtures
of probiotics, which may contain Sb, are avail-
able on the market, there is no evidence from
randomized controlled trials that these mixtures
are superior to the single strain preparations.
Moreover, potential limitation of probiotic mix-
tures is antagonism between the different probi-
otic strains and/or conflicting mechanisms of
actions that may tend to attenuate the therapeu-
tic responses of the probiotic strains9. What is
now clear is that the efficacy of probiotic prepa-
rations for treatment of gastrointestinal diseases
is related to individual microbial strains and
doses. We believe that probiotic preparations
should be regarded as drugs and physicians
should select those preparations for which evi-
dence of efficacy, or of greater efficacy in a giv-
en clinical condition, is supported by solid data.
Literature on Sb is wide and even more data be-
come available each year; thus, a second prob-
lem for a physician could derive from the diffi-
culty to summarize all the best informations de-
riving from basic research as well as from clini-
cal studies. With the aim to help physicians in
the use of Sb, this paper focuses on the available
evidences for its efficacy and safety in different
diseases in adult and pediatric patients in order
to provide a practical guidance for gastroen-
terology clinical practice.
To do this PubMed, Medline, and Google
Scholar were searched for articles unrestricted by
language  from 1983 to March 2011. Search term
included Sb, probiotics, gastroenterology, gas-
trointestinal tract, gut, intestine, infections, chil-
dren, pediatric patients, adult patients.
Mechanisms of Action of S. boulardii
A very active research in this field has provid-
ed interesting data on several mechanisms of ac-
tion of Sb. They may be classified into three
main areas: anti-microbial action, trophic action,
and immunoregulation.
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ovirus, Norovirus) are still very limited, and
further research in this field is advocated also
considering the epidemiologic importance of
these pathogens in clinical practice29. 
Trophic Action 
When Sb is given to antibiotic-shocked animal
or patients with diarrhea, normal microbiota is
re-established more rapidly. On the contrary, Sb
has no effect on microbiota composition in
healthy humans30-32. This effect is tightly linked
to a stimulation of short chain fatty acids (SCFA)
production, especially butyrate30,33,34. The pro-
duction of SCFAs is significantly decreased in
patients receiving antibiotics. The effect on bu-
tyrate production is particularly relevant consid-
ering the important role of this compound for the
regulation of many intestinal functions including,
the stimulation of enterocytes growth and differ-
entiation, fluid absorption, immune stimulation,
anti-inflammatory effects, enteric neurons
growth and differentiation34. These effects may
be especially relevant in the management of an-
tibiotic-associated diarrhea (AAD). S. boulardii
exerts trophic effects and enhances enzymes ex-
pression on microvilli of the host, it improves
disaccharidases activity, enhance the absorption
of D-glucose coupled to Na+ by the symport glu-
cose/Na+ and expression of the sodium-glucose
cotransporter-1 (SLGT-1)35 The yeast stimulates
the activity of sucrase at levels high enough to be
effective in the treatment of congenital sucrase-
isomaltase deficiency36,37. S. boulardii stimulates
mucosal peptidase activity and endoluminal pep-
tide hydrolysis in suckling rat small intestine,
and it was showed that this yeast  is also able to
produce and secrete in the intestinal lumen a
leucine aminopeptidase, belonging to the Zn2+-
metalloprotease family, with proteolytic activity
on endoluminal N-terminal of oligopeptides.
This effect could be potentially important in pre-
venting reactions to food antigens when mucosal
permeability is increased38. S. boulardii stimu-
lates the production of glycoproteins in the brush
border of microvilli such as hydrolases, trans-
porters, secretory IgA, and the receptor for poly-
meric immunoglobulins39. The production of in-
testinal polyamines induced and stimulated by Sb
is one of its most relevant and specific mecha-
nisms of action. The polyamines spermidine,
spermine, and putrescine enhance the expression
of brush border enzymes (such as hydrolases,
proteases, and transport molecules)35,40. In addi-
tion, Sb activates expression of peroxisome pro-
liferator-activated receptor-γ (PPAR-γ) that pro-
tects from gut inflammation and inflammatory
bowel diseases of the host41.
Immunoregulation 
The toxins elaborated by Clostridium difficile
and pathogenic bacteria, such as EPEC and en-
terohaemorragic E. coli (EHEC), activate the
MAP kinases ERK 1/2 and p38 as well as the
NF-kB (p65/p50) system leading to transcription
of pro-inflammatory genes such as interleukin 8
(IL-8) that promote inflammation. S. boulardii
inhibits MAP kinase and NF-κB signal transduc-
tion pathways and decreases the secretion of IL-8
and reducing inflammatory diarrhea. S. boulardii
also secretes a small (<1 kDa) heat-stable and
water-soluble anti-inflammatory factor termed
“S. boulardii anti-inflammatory factor” that in-
hibits the NF-κB-dependent signaling pathway in
the presence of C. difficile toxin42. The yeast also
decreases enterocyte apoptosis, probably as a re-
sult of the decrease of the synthesis of TNF-α43.
It has been recently postulated that Sb inhibits
dendritic cell-induced activation of naïve T
cells44. It also modifies the migration of lympho-
cytes in a model of inflammatory bowel disease
(IBD)45. Recent research demonstrated that the
supernatant of Sb cultures modifies the capacity
of lymphocytes to adhere to endothelial cells,
leading to improved cell rolling and adhesion45.
There is a very clear and marked stimulation of
production of IgA and specific IgG anti-toxins A
and B by C. difficile, as demonstrated by the in-
creased content in the intestinal lumen and in
crypt cells. This may be explained by a trophic
effect exerted on the mucosa or by direct im-
munostimulation39. Another mechanism indirect-
ly involved in the immune-regulation effect ex-
erted by Sb is the modulation of intestinal perme-
ability. Increased intestinal permeability is fre-
quently observed in different situations such as
following shock, burn injury, obstructive jaun-
dice, intestinal resection, hepatic transplant, or
intestinal obstruction (IO)46-50. A recent study has
demonstrated that in a murine IO model the oral
pretreatment  with  viable or heat  killed cells of
Sb, preserves intestinal integrity and modulates
inflammation, preventing bacterial translocation
and intestinal lesions51. Finally, it has been
demonstrated that Sb modulates the nitrogen ox-
ide pathway through the inhibition of the iNOS,
contributing to a general down-regulation of in-
testinal inflammation and an anti-secretory stim-
uli on transepithelial ion transport52.
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Evidences of Clinical Efficacy in Adults 
There are several randomized controlled trials
testing Sb in adult patients and mostly found a
significant protective effect elicited by this probi-
otic. Areas of interest include acute diseases
(AAD, acute diarrhea, traveler’s diarrhea, C. dif-
ficile infection, Helicobacter (H.) pylori disease,
enteral nutrition-related  diarrhea) and  chronic
conditions (Crohn’s disease, irritable bowel syn-
drome, giardiasis).
Antibiotic-Associated, Acute and 
Traveler’s Diarrhea
The efficacy of Sb in the prevention of AAD
has been tested in ten randomized controlled tri-
als (RCT)7,53-60. Eight of these (80%) showed a
significant efficacy in the prevention of the dis-
ease. A total number of 968 patients have been
treated  with Sb (doses ranging between 4×109 to
2×1010 cfu/day). A meta-analyses of these ten
studies showed that Sb was significantly protec-
tive for ADD with a risk of 0.47 (95% confi-
dence interval 0.35-0.63) and the number need-
ed-to-treat (NTT) in order to prevent one case of
ADD was 10.27. Among these studies, three trials
have been carried out on patients with H. pylori
infection receiving triple therapy, which is asso-
ciated with a high rate of ADD develop-
ment53,54,58. S. boulardii is able to decrease the
prevalence of ADD due to triple therapy so as to
eradicate H. pylori from 8.7% to 25% with re-
spects to placebo control.
Only two randomized controlled trials using Sb
showed that this probiotic may be effective in
treating acute diarrhea. In the first trial Sb was
able to improve the severity of diarrhea after 72
hours compared to placebo. The second study is a
RCT showing the efficacy of Sb in the treatment
of acute diarrhea caused by Entamoeba histolyti-
ca61. In this  study, 57 patients with acute dysen-
tery received metronidazole and iodiquinol for 10
days with and without Sb. All patients treated
with the yeast were cured when compared to 19%
of control patients. In a meta-analysis carried out
in order to evaluate 12 RCTs of various probiotics
for the prevention of traveler’s diarrhea, two
RCTs focused on Sb administered 5 days before
the trip and continued through the duration of the
trip showed the efficacy of this probiotic to re-
duce of traveler’s diarrhea in a dose-dependent
manner with the best effective daily dose of
2×1010 cfu62. No well-designed studies are avail-
able on the treatment of traveler’s diarrhea.
C. difficile Infection 
Four trials analyzed the use of Sb in C. difficile
infection (CDI). Two double-blinded RCTs in-
vestigated the use of Sb and antibiotics for pa-
tients with recurrent CDI. In the first, three an-
tibiotic regimens were used over a 10-day period
(either a high or low-dose of vancomycin or
metronidazole) combined with Sb or placebo.
After a 2-month follow-up, a significant decrease
of CDI recurrences was observed only in patients
treated with a high-dose of vancomycin and Sb
compared with antibiotic and placebo-treated
patients63. In the second double-blinded RCT, the
Authors verified a lower recurrence rate of CDI
disease in 57 patients on varied doses of van-
comycin or metronidazole and Sb (26.3%) com-
pared with 67 patients treated with antibiotic and
placebo (44.8%)64. The other two studies exam-
ined primary prevention of CDI in patient popu-
lations who were recently prescribed antibiotics
but showed no signs or symptoms of CDI55,65.
The presence of the C. difficile (verified by cul-
ture, or by the presence of toxin A and B) and
clinical outcomes of diarrhea were recorded.
However, these studies did not have the power to
detect statistically significant differences. Be-
cause only a small number of studies address the
primary prevention of CDI, more research is re-
quired before any changes in practice can be rec-
ommended with regard to using Sb in this
setting66.
Helicobacter pylori Eradication
Studies indicate that Sb may not be effective
enough to eradicate H. pylori but it decreases the
side-effects of the standard triple therapy. Indeed,
two trials have been performed on adult patients.
The first explored the efficacy of three probiotic
treatments (Sb, Lactobacillus rhamnosus GG or a
mixture of L. acidophilus and Bifidobacterium
lactis) or placebo associated with the triple thera-
py for the first week in asymptomatic H. pylori
carriers.  At the end of the second week, H. py-
lori eradication rates were similar for all groups,
but those regarding antibiotic-associated diarrhea
were lower (5%) in probiotic groups compared to
placebo (30%)58. The other study also assessed
Sb for both the eradication of H. pylori and the
reduction of side-effects relating to  standard an-
tibiotic treatment (53). This study involved 124
adults with H. pylori dyspepsia who were receiv-
ing the triple therapy and this was randomized
using either Sb or placebo. After six weeks there
was no significant difference in H. pylori eradi-
R. Berni Canani, S. Cucchiara, R. Cuomo, F. Pace, F. Papale
cation (71% in Sb vs 60% in placebo), whereas
significantly fewer patients randomized to Sb re-
ported epigastric distress (14.5%, p <0.05) com-
pared with placebo (43.5%), as well as lower
global dyspepsia symptom scores.
Enteral Nutrition-Related Diarrhea
Diarrhea is a common complication associated
with enteral feeding and this may result in a loss
of nutrients in an already seriously ill patient.
Three RCTs  have assessed the ability of Sb to re-
duce diarrhea in patients receiving enteral nutri-
tion. S. boulardii administered between 11 and 21
days was able to reduce diarrhea (8.7%) when
compared to the placebo (16.9%)67. In the other
two studies, patients under enteral nutrition treated
with Sb for a time varying between 8 and 28 days
had a significant fewer diarrheal episodes68,69.
Crohn’s Disease
Two randomized controlled clinical trials were
carried out testing Sb in patients suffering from
Crohn’s disease. In one RCT, 20 randomized pa-
tients, continuing their maintenance therapy,
were treated with either Sb or a placebo over a 7-
week period70. At the end of the study, patients
treated with Sb were significantly improved
when compared with those treated with placebo
(3.3±1.2 vs 4.6±1.9 stool movements/day). S.
boulardii added to mesalamine therapy was also
able to decrease the relapse rate in patients with
Crohn’s disease (n=32) observed over a 6-month
period (Sb+mesalamine 6% vs mesalamine alone
38%)71. 
Irritable Bowel Syndrome (IBS)
A recent study was aimed to evaluate the effects
on the quality of life (QOL) and symptoms in pa-
tients with diarrhea-predominant irritable bowel
syndrome IBS or mixed-type IBS. Sixty-seven pa-
tients with IBS were randomized either to receive
Sb or a placebo for 4 weeks. The overall improve-
ment in IBS-QOL was higher in the Sb group than
in the placebo-treated group (15.4% vs 7.0%;
p<0.05). Composite scores for IBS symptoms
were significantly reduced in both groups to a
similar extent. Bowel frequency and stool consis-
tency did not change in either group72.
Giardiasis 
S. boulardii has been also tested in giardiasis.
This condition is characterized by long-lasting
diarrhea with symptoms ranging from mild to se-
vere diarrhea, weight loss, abdominal pain and
weakness. In one study, 65 randomized adults
were treated to receive either Sb or placebo for
10 days. Both groups also received metronida-
zole for the same period of time. Two weeks lat-
er, both groups reported a resolution of their diar-
rhea, but none of those on Sb had detectable Gia-
rdia cysts, while significantly more (17%) on
placebo still carried Giardia cysts73.
Other Gastrointestinal Diseases
Potential uses of Sb were studied as regards
the treatment or the prevention of other condi-
tions such as HIV-1-related diarrhea. Indeed, 35
patients with HIV-1-related diarrhea were ran-
domized to receive either high daily doses of Sb
(6 × 1010 cfu) or a placebo for one week. More of
those patients given Sb (61%) had their diarrhea
resolved when compared with placebo (12%)74.
Indications regarding treatment with Sb were
also hypothesized for Blastocystis hominis infec-
tions. Recent data suggest that these infections
cause frequent symptoms and Sb is able to cure
the infections in a comparable manner with re-
spects to metronidazole75.
Evidences of Clinical Efficacy in Children
The pediatric clinical conditions in which Sb
has been investigated are mainly acute diarrhea,
persistent diarrhea, AAD, H. pylori infection. Al-
though its administration seems to have produced
healthy benefits in most of patients treated, only
few studies have been conducted in a well de-
signed manner or as controlled trials.
Acute Diarrhea
As for other probiotic products, the effect of
Sb on diarrhea is variable. It possibly depends on
disease severity, different clinical settings and
outcomes. Six RCTs investigated the potential
efficacy of Sb in children with acute diarrhea, in
5 significant reduction of total diarrhea duration
was demonstrated, in one no difference between
Sb and the control group was observed. However,
based on the pooled results of these six RCTs in-
volving 756 children, Sb compared to placebo or
no intervention, reduced the total duration of di-
arrhea by 22 hours (CI -26 to -18 hours). The da-
ta available in literature suggest that in otherwise
healthy infants and children with acute infectious
diarrhea (of viral or bacterial origin), the use of
Sb compared to controls is associated with mod-
erate therapeutic benefit that is reproducible re-
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gardless of the outcome measure studied (i.e. du-
ration of diarrhea, chance of cure or risk of diar-
rhea at certain point intervals, number of stools
and length of hospital stay)76. The European So-
ciety for Paediatric Gastroenterology, Hepatol-
ogy and Nutrition and the European Society of
Paediatric Infectious Diseases Expert Working
Group stated that selected probiotics may be an
effective adjunct to the management of diarrhea.
However, because there is no evidence of effica-
cy for many preparations, only probiotic strains
with proven clinical efficacy and in appropriate
dosage are recommended as an adjunct for the
management of children with acute gastroenteri-
tis to rehydration therapy. Lactobacillus GG and
Sb constituted examples of probiotics that
showed benefit77. In a recent double-blind RCT
children with acute Rotavirus diarrhea  received
one of two treatments (oral rehydration solution
plus Sb or plus a compound containing Lacto-
bacillus acidophilus, Lactobacillus rhamnosus,
Bifidobacterium longum and Sb) or placebo. Re-
sults showed that both products decreased the du-
ration of diarrhea compared to oral rehydration
solution alone, but only for the single species
product (containing Sb) the decrease was signifi-
cant, children in this group showed a decrease in
fever duration78. Another recent trial evaluated
the clinical efficacy and cost/effectiveness of Sb
compared with yogurt fluid (YF) in acute non-
bloody diarrhea in children. This randomized,
prospective open-label clinical trial included 55
children (36 boys, mean age 21.2±28.2 months).
Group A (n=28) received lyophilized Sb and
group B (n=27) received YF. The duration of di-
arrhea was shorter with Sb but the hospital stay
was reduced with YF, although these differences
were not significant. However, on day 3 the rate
of children with diarrhea was lower in the Sb
group (48.5% versus 25.5%; p < 0.05)79.
Antibiotic Associated Diarrhea (AAD)
Three RCTs investigated the potential efficacy
of Sb in the prevention of AAD in children, in
two a significant reduction of total  prevalence of
diarrhea was demonstrated80. In one no differ-
ence between Sb and the control group was ob-
served. But it should be stated that in this study
diosmectite was used in the control group. How-
ever, in the two studies showing an efficacy of Sb
in the prevention of AAD a RR 0.3, 95% CI 0.2
to 0.5 and 0.3 95% CI 0.2 to 0.7, was observed
respectively. Very limited data are available in
children with AAD or with CDI treated with
Sb81. A recent case report suggest the potential
utility of Sb for recurrent CDI in a child with sur-
gically treated Hirschsprung’s disease. The pa-
tient had several intermittent episodes of CDI,
and significant benefits were derived from Sb
therapy, with reduction in frequency and severity
of episodes. The child was more medically stable
during the subsequent episodes, and there was
less consequent disruption to the child’s develop-
mental and psychosocial well-being82.
Persistent Diarrhea
Persistent diarrhea is defined by WHO as an
episode which starts acutely but which persists
for 14 days or longer. The main dangers of persis-
tent diarrhea are malnutrition and severe extra-in-
testinal infections. The morbidity and mortality of
persistent diarrhea and the magnitude of the prob-
lem, particularly in the developing world, justify
any attempt to improve treatments83. To determine
whether treatment with Sb improves outcomes in
children with persistent diarrhea a RCT was con-
ducted in 89 children (age range 6-24 months) al-
located to receive pasteurized cow’s milk supple-
mented with two viable lyophilized strains Lacto-
bacillus casei and L. acidophilus strains
1010–1012cfu/g (n=30), or lyophilized Sb 1010-
1012cfu/g (n=30), or pasteurized cow’s milk as
placebo (n=29), twice a day for 5 days. Enteric
pathogens (Rotavirus, E. coli, Salmonella, Shigel-
la) were isolated from the stools in 40% of the
patients, 27% had Rotavirus. Lactobacillus strains
and Sb significantly reduced the number of stools
per day (p<0.001) and diarrhea duration
(p<0.005)84. Another trial was carried out in 40
children (aged 6 to 36 months) with diarrhea of 3
or 4weeks duration were randomized to receive
Sb at a dose of 1x1010 cfu/day (n=20) or placebo
(n=20) for 1 month. All patients received either
tinidazole for Giardia lamblia (87.5%) or trime-
toprim plus sulfamethoxazole for Shigella just
prior to the intervention. At the end of the study,
the percentage of children with <3 bowel move-
ments per day was significantly higher in the Sb
group compared to the placebo group (65% vs
15%, p=0.002)85. Taken together, these results
suggest that Sb could be useful in the manage-
ment of persistent diarrhea in children.
Helicobacter pylori Infection
S. boulardii plus inulin could hold promise as
an adjunctive agent to the triple therapy. This is
based on the results of one open RCT evaluating
whether consumption of either the combination
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of Sb plus inulin or of L.acidophilus LB would
affect H. pylori eradication in the pediatric popu-
lation. Two hundred and fifty-four asymptomatic
children, who were positive for H. pylori infec-
tion by the 13C-urea breath test, were allocated to
one of three groups: (1) 8-day course of eradica-
tion triple therapy with lanzoprazole, amoxi-
cillin, and clarithromycin; (2) L.acidophilus LB;
and (3) a symbiotic (Sb plus inulin). H. pylori
was eradicated in 66% (30/45), 12% (6/51), and
6.5% (3/46) of the children from the antibiotic
group, symbiotic group, and probiotic groups, re-
spectively (p<0.001)86. Although the eradication
rate of H. pylori with Sb is low, further studies
elucidating the mechanisms by which Sb with or
without additional inulin may inhibit H. pylori
would be of interest.
Blastocystis Hominis Infection
The pathogenic potential of B. hominis re-
mains controversial and up to now there is a con-
sensus that therapy should be limited to patients
with persistent unexplained symptoms after an
accurate evaluation and a complete negative
screening for alternative etiologies. Metronida-
zole is the most recommended agent in the treat-
ment for B. hominis infection87. Also if some da-
ta suggest no beneficial effects for blastocystosis
(88). A recent study has demonstrated the poten-
tial beneficial effects in B. hominis infection
(symptoms, presence of parasites) in children
treated with metronidazole or Sb. Three groups
were analyzed: group A, treated with Sb (250 mg
twice a day) for 10 days; group B, treated with
metronidazole (30 mg/kg twice daily) for
10 days; and for group C no treatment was pro-
vided. On day 15, clinical cure was observed in
77.7% in group A (n=18); in 66.6% in group B
(n=15); and 40% in group C (n=15) (p<0.031,
between groups A and C). Disappearance of the
cysts from the stools on day 15 was 80.0% in
group B, 72.2% in group A, and 26.6% in group
C (p=0.011, between group B and group C;
p=0.013, between group A and group C). At the
end of the first month after enrolment, clinical
cure rate was 94.4% in group A and 73.3% in
group B (p=0.11). Stool presence resulted nega-
tive for B. hominis in a similar way in both
groups (94.4% vs. 93.3%, p=0.43)89. 
Amebiasis
In a recent study the addition of Sb (0.5×1010
cfu/mg) to metronidazole for a 7-day treatment
of acute bloody diarrhea due to intestinal caused
by Entameba histolytica resulted in a significant
decrease of  diarrhea duration and enhance of the
gastrointestinal clearance of the amebic cysts,
compared to  treatment with metronidazole
alone90.
Pharmacokinetics 
S. boulardii is generally administered in
lyophilized powder corresponding to approxi-
mately 3×1010cfu/gr. Unless exogenously admin-
istered it is not found as part of the intestinal mi-
croflora of humans and under normal conditions
it doesn’t permanently colonize the gastrointesti-
nal tract. Daily administration as lyophilized
powder guarantees vital persistence of yeast
along the whole gastrointestinal tract. In fact, this
yeast, because of its peculiarity it’s not absorbed,
it has no systemic impact, is resistant to gastric
acids and to bile secretions and, within 48-120
hours since the end of treatment, at usual doses,
is not anymore detectable in the stools. Pharma-
cokinetics studies indicate that Sb is able to reach
fast and high concentrations in the colon without
colonizing it91. In human adult volunteers, fol-
lowing a single oral 1g dose maximal stool con-
centration was achieved between 36 and 60 hours
post-dose and after 2-5 days the levels were be-
low the limit of detection92. 
Stability
Probiotic product manufacturing may affect its
shelf-life. Probiotics may be available as
lyophilized or heat-dried preparations or con-
tained in diary or drink food products. Heat-dried
capsule products may be identified by their la-
bels, which usually state that the products should
be refrigerated after opening and they lose their
potency rapidly. Lyophilized preparations of Sb
are stable over one year at room temperature, as
long as it is protected from moisture93, and have
the advantage of portability and convenience and
maintain high viability counts over prolonged pe-
riods. Heat-dried preparations are not stable at
room temperature and must be refrigerated7.
Safety
Safety and adverse event data collected have
documented a remarkable safety profile for Sb in
otherwise healthy patients (adults and children)
with AAD, infections of the gastrointestinal tract,
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IBD, IBS receiving this yeast by oral route. Also in
HIV-1-infected patients the therapy with Sb result-
ed to be safe74. Infrequent cases of fungemia have
been reported in case reports or case series. Most
of them presented severe co-morbidities and have
central venous catheters. In some of these patients
yeast was acquired from contaminated environ-
mental fomites94. S. boulardii in the formulations
actually on the market in Europe are gluten free,
and may be administered also during pregnancy
and suckling. Finally, also if the risks of adminis-
tering Sb seem to be minimal compared with
placebo, adverse reactions are not excluded. A case
report described the occurrence of allergic reaction
caused by Sb95, and patients receiving treatment
with Sb for the prevention of CDI experienced in-
creased risk for thirst and constipation7.
Contraindications/Precautions
Use in patients who have central venous
catheters is generally contraindicated. Unlike many
bacterial probiotics, there are few drug or antibiotic
interactions with Sb. However, if patients are on an-
ti-fungal medications, a staggered dose regime (at
least 4 h apart) is suggested96. A critical cost/benefit
ratio should be considered before the use of probi-
otics in severely ill patients, for a possible increased
risk of systemic infections.
Future Research Perspectives
and Conclusions
S. boulardii has been used as probiotic since
1950, and it has been investigated in in vitro
studies in different experimental models and in
several clinical trials worldwide in adult as well
in paediatric patients. Not many other examples
of a similar amount of data on a single probiotic
is currently available in the scientific literature.
The use of Sb as preventive and therapeutic strat-
egy is supported by convincing data on its mech-
anism of action, pharmacokinetics, and efficacy
in several conditions. A summary of indications
and recommended  doses for the clinical use of
Sb in gastroenterology clinical practice is provid-
ed in Table I. The strength of evidence is high for
the prevention of AAD and for TD in adult pa-
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Daily Doses – cfu/day (mg/day)
Disease Adult patients Pediatric patients
Prevention
Antibiotic-associated diarrhea 1-2 × 1010 (500-1000) during 1 × 1010 (500) during the
the entire duration of antibiotic entire duration of antibiotic
therapy plus 3 d to 2 wks after therapy plus 7-9 d after
Traveler’s diarrhea 0.5-2 × 1010 (250-1000) for 5 d
prior the trip and continued
through the duration of the trip 
Enteral nutrition-related diarrhea 4 × 1010 (2000) for 8-28 d
H. pylori eradication therapy side-effects 2 × 1010 (1000) for 2 wk
Relapses in Crohn’s disease 1.5-2 × 1010 (750-1000) up to 6 mo
Treatment
C. difficile infection 2 × 1010 (1000) for 4 wk
Acute diarrhea 1.5-2 × 1010 (750-1000) for 8-10 d < 1y of age 0.5 × 1010 (250)
for 5-6 d
> 1y of age 1 × 1010 (500)
for 5-6 d
Irritable bowel syndrome 1 × 1010 (500) for 4 wk
Giardiasis 1 ×1 010 (500) for 4 wk
HIV-related diarrhea 6 × 1010 (3000) for 7 d
Persistent diarrhea 1 × 1010 (500) for 1 to 4 wk
Table I. Summary of the main clinical indications and recommended doses for the clinical use of S. boulardii in gastroenterol-
ogy clinical practice.
Note: 1 × 1010 cfu of Sb correspond to 500 mg of dried power of the yeast in the commercially available products. Legend: d =
day; wk = week; mo = month; y = year.
tients, and for the treatment of acute and persis-
tent diarrhea and prevention of AAD in children.
More studies are encouraged for other conditions
referred in the Table II and for a better definition
of mechanisms of action of this probiotic in se-
lected diseases of the gastrointestinal tract. The
quality of products available on the market is
generally good but more research could be neces-
sary to obtain new formulations even more sta-
ble, efficacious  and practical for a wide clinical
use even in pediatric patients, such as drops. In
this light, are of particular interest recent data on
new formulation of Sb, encapsulated in food-
grade whey protein isolate (WP) and alginate
(ALG) micro-particles, in order to protect and
vehicle the yeast in gastrointestinal environ-
ment97. We know that a large proportion of the
yeast is inactivated after oral administration98, the
gastrointestinal survival of the yeast in these mi-
cro-particles resulted significantly increased
(40% vs 10%) and was further improved to 60%
by coating. Coated WP/ALG micro-particles ap-
pear to have potential as oral delivery systems for
Sb in pharmaceutical or food processing applica-
tions, and because this encapsulation system re-
quires  only food-grade components is, therefore,
compatible with pharmaceutical requirements in
terms of safety and biocompatibility. Recently,
beneficial effect are demonstrated when the com-
bined administration of Sb with zinc are used in
the treatment of Rotavirus diarrhea in hospital-
ized children99. Zinc is a potent agent against in-
fectious diarrheas100, and the results of this study
suggests the potential utility of a new formula-
tion of Sb containing zinc that could result in a
even more effective treatment for these very
common disorders. This research together with
new investigation on the use of Sb in the early in-
fancy, including the neonatal period, could open
the way to new possible clinical indications for
prevention and treatment of pediatric diseases.
For example, it has been recently demonstrated
that children affected by cow’s milk allergy, the
most common food allergy in the pediatric age
worldwide, have very few amounts of Sb in their
intestinal microflora compared to healthy con-
trols101. Thus, also considering the several im-
munoregolatory effects exerted by Sb at intestinal
level,  it could be interesting to investigate the ef-
ficacy of this probiotic in the prevention or treat-
ment of food allergies. Finally, isolated yeast
components could also be administered as thera-
peutics. Although this approach extends beyond
the official definition of probiotics (defined as
living microbes), it does not differ much in con-
cept from vaccination, the administration of mi-
crobial components to stimulate selected immune
functions. The use of nonviable yeast or yeast
components would also avoid the risk of sepsis
or other potential complication of probiotics, par-
ticularly in critically ill patients with compro-
mised intestinal barrier function. As stated
above, Sb produces several peptides and other
compounds able to exert immune and non-im-
mune effects of potential clinical importance also
when administered alone, and this could be open
the way  to an innovative “pharmacobiotical ap-
proach” in human medicine deriving from this
yeast. Strictly correlated to these possible ap-
proaches are the interesting data deriving from
investigation on the effect of fermentation with
Sb. A recent study suggest the utility of fermen-
tation with Sb on rice bran. This study showed
that different rice varieties fermented with Sb are
able to reduce the growth of human B lym-
phomas compared to each variety’s non-ferment-
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Clinical indications Mechanisms of action
• Acute diarrhea in adults • Rotavirus and other virus-induced diarrheal disorders
• Traveler’s diarrhea • Structure and effects of peptides and other compounds
produced by Sb
• Inflammatory bowel disease • Effects of mixtures of probiotics containing Sb
• Irritable bowel syndrome • Effects of products containing Sb plus zinc
• H. pylori infection • Effects of the addition of Sb to foods regarding the
bioavailability of antigen epitopes and micronutrients
• Persistent diarrhea
• C. albicans infection
• Food allergy
Table II. The research agenda for future studies for a better definition of the S. boulardii use in gastroenterology clinical practice.
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ed control and revealed that fermentation differ-
entially altered bioactive compounds. This re-
search could open the way to new studies explor-
ing the effects of the addition of Sb to foods re-
garding the bioavailability of new compounds
with biological effects. And this could be also of
importance regarding the potential modulation of
antigenic epitopes and micronutrients bioavail-
ability deriving from the fermentation with Sb of
certain foods. This approach has been suggested
for food allergies and for celiac disease using dif-
ferent probiotics, but data on Sb are still limit-
ed102. Finally, probiotics are currently used in
many baby foods with the aim to improve the
wellness of the consumers protecting them from
several diseases, in particular from infectious or
immune-mediated disorders, but also in this case
the experience with Sb is still limited. 
In conclusion, studying well established probi-
otics (such as S. boulardii) basic scientists, clini-
cal researchers and industrial leaders have the
opportunity to work together against different
diseases of gastrointestinal tract with great social
and economic impact. Some beneficial effects of
Sb need to be better defined and the molecular
mechanisms that underlie these effects need to be
investigated in detail. The compounds mediating
these effects should be purified and identified,
and may eventually be used for pharmaceutical
purposes. Synergistic effects should also be in-
vestigated, together with the positive contribution
of specific prebiotics. This yeast has an addition-
al quality: it generally can be grown in cheap
products and foods and, therefore, can contribute
to gastrointestinal disease cure and prevention in
both developed and developing countries.
–––––––––––––––––––
Acknowledgements
The Authors thank Dr. Anna Buongiovanni for the pre-
cious help in text editing.
References
1) DE VRESE M, SCHREZENMEIR J. Probiotics, prebiotics,
synbiotics. Adv Biochem Eng Biotechnol 2008;
111: 1-66.
2) ANTOINE JM. Probiotics: beneficial factors of the de-
fence system. Proc Nutr Soc 2010; 69: 429-433.
3) OHLAND CL, MACNAUGHTON WK. Probiotic bacteria
and intestinal epithelial barrier function. Am J
Physiol Gastrointest Liver Physiol 2010; 298:
G807-819.
4) MCFARLAND LV. Saccharomyces boulardii is not
Saccharomyces cerevisiae. Clin Infect Dis 1996;
22: 200-201
5) MITTERDORFER G, MAYER HK, KNEIFEL W, VIERNSTEIN H.
Clustering of Saccharomyces boulardii strains
within the species S.cerevisiae using molecular
typing techniques. J Appl Microbiol 2002; 93: 521-
530.
6) FIETTO JL, ARAÚJO RS, VALADÃO FN, FIETTO LG,
BRANDÃO RL, NEVES MJ, GOMES FC, NICOLI JR, CAS-
TRO IM. Molecular and physiological comparisons
between Saccharomyces cerevisie and Saccha-
romyces boulardii. Can J Microbiol 2004; 50: 615-
621.
7) McFarland LV. Systematic review and meta-analy-
sis of Saccharomyces boulardii in adult patients.
World J Gastroenterol 2010; 16: 2202-2222.
8) MARTINS FS, NARDI RM, ARANTES RM, ROSA CA, NEVES
MJ, NICOLI JR. Screening of yeasts as probiotic
based on capacities to colonize the gastrointesti-
nal tract and to protect against enteropathogen
challenge in mice. J Gen Appl Microbiol 2005; 51:
83-92.
9) MYLLYLUOMA E, AHONEN AM, KORPELA R, VAPAATALO
H, KANKURI E. Effects of multispecies probiotic
combination on Helicobacter pylori infection in vit-
ro. Clin Vaccine Immunol 2008; 15: 1472-1482.
10) CASTAGLIUOLO I, LAMONT JT, NIKULASSON ST,
POTHOULAKIS C. Saccharomyces boulardii protease
inhibits Clostridium difficile toxin A effects in the
rat ileum. Infect Immun 1996; 64: 5225-5232.
11) CASTAGLIUOLO I, RIEGLER MF, VALENICK L, LAMONT JT,
POTHOULAKIS C. Saccharomyces boulardii protease
inhibits the effects of Clostridium difficile toxins A
and B in human colonic mucosa. Infect Immun
1999; 67: 302-307.
12) BRANDÃO RL, CASTRO IM, BAMBIRRA EA, AMARAL SC, FI-
ETTO LG, TROPIA MJ, NEVES MJ, DOS SANTOS RG,
GOMES NC, NICOLI JR. Intracellular signal triggered
by cholera toxin in Saccharomyces boulardii and
Saccharomyces cerevisiae. Appl Environ Microbi-
ol 1998; 64: 564-568.
13) CZERUCKA D, RAMPAL P. Effect of Saccharomyces
boulardii on cAMP- and Ca2+-dependent Cl- se-
cretion in T84 cells. Dig Dis Sci 1999; 44: 2359-
2368.
14) BUTS JP, DEKEYSER N, STILMANT C, DELEM E, SMETS F,
SOKAL E. Saccharomyces boulardii produces in rat
small intestine a novel protein phosphatase that
inhibits Escherichia coli endotoxin by dephospho-
rylation. Pediatr Res 2006; 60: 24-29. 
15) MUMY KL, CHEN X, KELLY CP, MCCORMICK BA. Sac-
charomyces boulardii interferes with Shigella
pathogenesis by post-invasion signaling events.
R. Berni Canani, S. Cucchiara, R. Cuomo, F. Pace, F. Papale
Am J Physiol Gastrointest Liver Physiol 2008;
294: G599-609.
16) ZBINDEN R, BONCZI E, ALTWEGG M. Inhibition of Sac-
charomyces boulardii on cell invasion of Salmo-
nella typhimurium and Yersinia enterocolitica. Mi-
cro Ecol Health Dis 1999; 11: 158-162. 
17) ALTWEGG M, SCHNACK J, ZBINDEN R. Influence of
Saccharomyces boulardii on Aeromonas he-
molysin. Med Microbiol Lett 1995; 4: 417-425.
18) DAHAN S, DALMASSO G, IMBERT V, PEYRON JF, RAMPAL P,
CZERUCKA D. Saccharomyces boulardii interferes
with enterohemorrhagic Escherichia coli-induced
signaling pathways in T84 cells. Infect Immun
2003; 71: 766-773.
19) WU X, VALLANCE BA, BOYER L, BERGSTROM KS, WALKER
J, MADSEN K, O’KUSKY JR, BUCHAN AM, JACOBSON K.
Saccharomyces boulardii ameliorates Citrobacter
rodentium-induced colitis through actions on bac-
terial virulence factors. Am J Physiol (Gastrointest
Liver Physiol) 2008; 294: G295-306. 
20) LESSARD M, DUPUIS M, GAGNON N, NADEAU E, MATTE
JJ, GOULET J, FAIRBROTHER JM. Administration of Pe-
diococcus acidilactici or Saccharomyces cerevisi-
ae boulardii modulates development of porcine
mucosal immunity and reduces intestinal bacteri-
al translocation after Escherichia coli challenge. J
Anim Sci 2009; 87: 922-934.
21) KAREN M, YUKSEL O, AKYÜREK N, OFLUOĞLU E, CAĞLAR
K, SAHIN TT, PAŞAOĞLU H, MEMIŞ L, AKYÜREK N,
BOSTANCI H. Probiotic agent Saccharomyces
boulardii reduces the incidence of lung injury in
acute necrotizing pancreatitis induced rats. J Surg
Res 2010; 160: 139-144.
22) ZAOUCHE A, LOUKIL C, DE LAGAUSIE P, PEUCHMAUR M,
MACRY J, FITOUSSI F, BERNASCONI P, BINGEN E, CEZARD
JP. Effects of oral Saccharomyces boulardii on
bacterial overgrowth, translocation, and intestinal
adaptation after small-bowel resection in rats.
Scand J Gastroenterol 2000; 35: 160-165. 
23) TASTEYRE A, BARC MC, KARJALAINEN T, BOURLIOUX P,
COLLIGNON A. Inhibition of in vitro cell adherence
of Clostr idium diff ici le by Saccharomyces
boulardii. Microb Pathog 2002; 32: 219-225.
24) CZERUCKA D, DAHAN S, MOGRABI B, ROSSI B, RAMPAL P.
Saccharomyces boulardii preserves the barrier
function and modulates the signal transduction
pathway induced in enteropathogenic Escherichia
coli-infected T84 cells. Infect Immun 2000; 68:
5998-6004.
25) GEDEK BR. Adherence of Escherichia coli
serogroup O 157 and the Salmonella typhimuri-
um mutant DT 104 to the surface of Saccha-
romyces boulardii. Mycoses 1999; 42: 261-264. 
26) MURZYN A, KRASOWSKA A, AUGUSTYNIAK D, MAJKOWSKA-
SKROBEK G, ŁUKASZEWICZ M,DZIADKOWIEC D. The ef-
fect of Saccharomyces boulardii on Candida albi-
cans-infected human intestinal cell lines Caco-2
and Intestin 407. FEMS Microbiol Lett 2010; 310:
17-23.
27) MURZYN A, KRASOWSKA A, STEFANOWICZ P, DZIADKOWIEC
D, ŁUKASZEWICZ M. Capric acid secreted by S.
boulardii inhibits C. albicans filamentous growth,
adhesion and biofilm formation. PLoS One 2010;
5: e12050.
28) SAMONIS G, FALAGAS ME, LIONAKIS S, NTAOUKAKIS M,
KOFTERIDIS DP, NTALAS I,MARAKI S. Saccharomyces
boulardii and Candida albicans experimental col-
onization of the murine gut. Med Mycol 2010; Nov
15.
29) COLBÈRE-GARAPIN F, MARTIN-LATIL S, BLONDEL B, MOUS-
SON L, PELLETIER I, AUTRET A, FRANÇOIS A, NIBORSKI V,
GROMPONE G, CATONNET G, VAN DE MOER A. Preven-
tion and treatment of enteric viral infections: pos-
sible benefits of probiotic bacteria. Microbes In-
fect 2007; 9: 1623-1631.
30) OIRARD-PIPAU F, POMPEI A, SCHNEIDER S, NANO JL,
HEBUTERNE X, BOQUET P, RAMPAL P. Intestinal mi-
croflora, short chain and cellular fatty acids, influ-
ence of a probiotic S. boulardii. Microb Ecology
Health Dis 2002; 14: 220-227. 
31) SWIDSINSKI A, LOENING-BAUCKE V, VERSTRAELEN H, OS-
OWSKA S, DOERFFEL Y. Biostructure of fecal micro-
biota in healthy subjects and patients with chronic
idiopathic diarrhea. Gastroenterology 2008; 135:
568-579. 
32) BARC MC, CHARRIN-SARNEL C, ROCHET V, BOURLIOUX F,
SANDRÉ C, BOUREAU H, DORÉ J, COLLIGNON A. Molec-
ular analysis of the digestive microbiota in a gno-
tobiotic mouse model during antibiotic treatment:
Influence of Saccharomyces boulardii. Anaerobe
2008; 14: 229-233. 
33) BREVES G, WALTER C, BURMESTER M, SCHRÖDER B. In
vitro studies on the effects of Saccharomyces
boulardii and Bacillus cereus var. toyoi on nutrient
transport in pig jejunum. J Anim Physiol 2000: 84:
9-20.
34) SCHNEIDER SM, GIRARD-PIPAU F, FILIPPI J, HEBUTERNE X,
MOYSE D, HINOJOSA GC, POMPEI A, RAMPAL P. Effects
of Saccharomyces boulardii on fecal short-chain
fatty acids and microflora in patients on long-term
total enteral nutrition. World J Gastroenterol 2005;
1: 6165-6169. 
35) BUTS JP, DE KEYSER N, DE RAEDEMAEKER L. Saccha-
romyces boulardii enhances rat intestinal enzyme
expression by endoluminal release of polyamines.
Pediatr Res 1994; 36: 522-527.
36) BUTS JP, DE KEYSER N, MARANDI S. Saccharomyces
boulardii upgrades cellular adaptation after proxi-
mal enterectomy in rats. Gut 1999; 45: 89-96.
37) ZAOUCHE A, LOUKIL C, DE LAGAUSIE P, PEUCHMAUR M,
MACRY J, FITOUSSI F, BERNASCONI P, BINGEN E, CEZARD
JP. Effects of oral Saccharomyces boulardii on
bacterial overgrowth, translocation, and intestinal
adaptation after small-bowel resection in rats.
Scand J Gastroenterol 2000; 35: 160-165.
38) BUTS JP, DE KEYSER N, STILMANT C, SOKAL E, MARANDI
S. Saccharomyces boulardii enhances N-terminal
peptide hydrolysis in suckling rat small intestine
819
S. boulardii in gastroenterology clinical practice
820
by endoluminal release of a zinc-binding metallo-
protease. Pediatr Res 2002; 51: 528-534.
39) OZKAN TB, SAHIN E, ERDEMIR G, BUDAK F. Effect of
Saccharomyces boulardii in children with acute
gastroenteritis and its relationship to the immune
response. J Int Med Res 2007; 35: 201-212.
40) BUTS JP, DE KEYSER N. Effects of Saccharomyces
boulardii on intestinal mucosa. Dig Dis Sci 2006;
51: 1485-1492.
41) POTHOULAKIS C. Review article: anti-inflammatory
mechanisms of action of Saccharomyces
boulardii. Aliment Pharmacol Ther 2009; 30: 826-
833.
42) SOUGIOULTZIS S, SIMEONIDIS S, BHASKAR KR, CHEN X,
ANTON PM, KEATES S, POTHOULAKIS C, KELLY CP. Sac-
charomyces boulardii produces a soluble anti-in-
flammatory factor that inhibits NF-kappaB-medi-
ated IL-8 gene expression. Biochem Biophys Res
Commun 2006; 343: 69-76.
43) SHERMAN PM, JOHNSON-HENRY KC, YEUNG HP, NGO
PSC, GOULET J, THOMPKINS TA. Probiotics reduce en-
terohemorrhagic Escherichia coli-0157:H7-en-
teropathogenic E. coli 0127:H6-induced changes
in polarized T84 epithelial cell monolayers by re-
ducing bacterial adhesion and cytoskeletal re-
arrangements . Infect Immun 2005; 73: 5183-
5188. 
44) BAUMGART D. The probiotic yeast Saccharomyces
boulardii inhibits DC-induced activation of naïve
T-cells. Gastroenterology 2007; 13(Suppl 1): A-
559. 
45) DALMASSO G, COTTREZ F, IMBERT V, LAGADEC P, PEYRON
JF, RAMPAL P, CZERUCKA D,GROUX H, FOUSSAT A, BRUN
V. Saccharomyces boulardii inhibits inflammatory
bowel disease by trapping T cells in mesenteric
lymph nodes. Gastroenterology 2006; 131: 1812-
1825.
46) SEEHOFER D, RAYES N, SCHILLER R, STOCKMANN M,
MÜLLER AR, SCHIRMEIER A, SCHAEPER F, TULLIUS SG,
BENGMARK S, NEUHAUS P. Probiotics partly reverse
increased bacterial translocation after simultane-
ous liver resection and colonic anastomosis in
rats. J Surg Res 2004; 117: 262-271. 
47) DEMIRER S, AYDINTUG S, ASLIM B, KEPENEKCI I, SENGÜL
N, EVIRGEN O, GERCEKER D, ANDRIEU MN, ULUSOY C,
KARAHÜSEYINOGLU S. Effects of probiotics on radia-
tion-induced intestinal injury in rats. Nutrition
2005; 22: 179-186.
48) GEYIK MF, ALDEMIR M, HOSOGLU S, AYAZ C, SATILMIS S,
BUYUKBAYRAM H, KOKOGLU OF. The effects of Sac-
charomyces boulardii on bacterial translocation in
rats with obstructive jaundice. Ann R Coll Surg
Engl 2006; 88: 176-180.
49) MOGILNER JG, SRUGO I, LURIE M, SHAOUL R, CORAN
AG, SHILONI E, SUKHOTNIK I. Effect of probiotics on
intestinal regrowth and bacterial translocation af-
ter massive small bowel resection in a rat. J Pedi-
atr Surg 2007; 42: 1365-1371.
50) QUIRINO IEP, CORREIA MITD, CARDOSO VN. The im-
pact of arginine on bacterial translocation in an
intestinal obstruction model in rats. Clin Nutr
2007; 26: 335-340.
51) GENEROSO SV, VIANA ML, SANTOS RG, ARANTES RM,
MARTINS FS, NICOLI JR, MACHADO JA, CORREIA MI,
CARDOSO VN. Protection against increased intesti-
nal permeability and bacterial translocation in-
duced by intestinal obstruction in mice treated
with viable and heat-kil led Saccharomyces
boulardii. Eur J Nutr 2010; Oct 10
52) GIRARD P, PANSART Y, LORETTE I, GILLARDIN JM.
Dose–response relationship and mechanism of
action of Saccharomyces boulardii in castor oil-in-
duced diarrhea in rats. Dig Dis Sci 2003; 48: 770-
774. 
53) CINDORUK M, ERKAN G, KARAKAN T, DURSUN A, UNAL
S. Efficacy and safety of Saccharomyces boulardii
in the 14-day triple anti-Helicobacter pylori thera-
py: a prospective randomized placebo-controlled
double-blind study. Helicobacter 2007; 12: 309-
316.
54) DUMAN DG, BOR S, OZÜTEMIZ O, SAHIN T, OĞUZ D,
IŞTAN F, VURAL T, SANDKCI M, IŞKSAL F, SIMŞEK I,
SOYTÜRK M, ARSLAN S, SIVRI B, SOYKAN I, TEMIZKAN A,
BESSK F, KAYMAKOGLU S, KALAYC C. Efficacy and safe-
ty of Saccharomyces boulardii in prevention of
antibiotic-associated diarrhoea due to Helicobac-
ter pylori eradication. Eur J Gastroenterol Hepatol
2005; 17: 1357-1361.
55) MCFARLAND LV, SURAWICZ CM, GREENBERG RN, ELMER
GW, MOYER KA, MELCHER SA, BOWEN KE, COX JL.
Prevention of beta-lactam-associated diarrhea by
Saccharomyces boulardii compared with placebo.
Am J Gastroenterol 1995; 90: 439-448.
56) SURAWICZ CM, ELMER GW, SPEELMAN P, MCFARLAND LV,
CHINN J, VAN BELLE G. Prevention of antibiotic-asso-
ciated diarrhea by Saccharomyces boulardii: a
prospective study. Gastroenterology 1989; 96:
981-988.
57) LEWIS SJ, POTTS LF, BARRY RE. The lack of therapeu-
tic effect of Saccharomyces boulardii in the pre-
vention of antibiotic-related diarrhoea in elderly
patients. J Infect 1998; 36: 171-174.
58) CREMONINI F, DI CARO S, COVINO M, ARMUZZI A,
GABRIELLI M, SANTARELLI L, NISTA EC, CAMMAROTA G,
GASBARRINI G, GASBARRINI A. Effect of different probi-
otic preparations on anti Helicobacter pylori thera-
py-related side effects: a parallel group, triple
blind, placebo-controlled study. Am J Gastroen-
terol 2002; 97: 2744-2749.
59) CAN M, BE IRBELLIOGLU BA, AVCI IY, BEKER CM, PAHSA
A. Prophylactic Saccharomyces boulardii in the
prevention of antibiotic-associated diarrhea: a
prospective study. Med Sci Monit 2006; 12: 19-22.
60) BRAVO MV, BUNOUT D, LEIVA L, DE LA MAZA MP, BAR-
RERA G, DE LA MAZA J, HIRSCH S. Effect of probiotic
Saccharomyces boulardii on prevention of antibi-
otic-associated diarrhea in adult outpatients with
R. Berni Canani, S. Cucchiara, R. Cuomo, F. Pace, F. Papale
amoxicillin treatment. Rev Med Chil 2008; 136:
981-988.
61) MANSOUR-GHANAEI F, DEHBASHI N, YAZDANPARAST K,
SHAFAGHI A. Efficacy of Saccharomyces boulardii
with antibiotics in acute amoebiasis. World J Gas-
troenterol 2003; 9: 1832-1833.
62) McFarland LV. Meta-analysis of probiotics for the
prevention of traveler’s diarrhea. Travel Med Infect
Dis 2007; 5: 97-105.
63) MCFARLAND LV, SURAWICZ CM, GREENBERG, FEKETY R,
ELMER GW, MOYER KAQ, MELCHER SA, BOWEN KE,
COX JL, NOORANI Z. A randomized placebo-con-
trolled trial of Saccharomyces boulardii in combi-
nation with standard antibiotics for Clostridium dif-
ficile disease. JAMA 1994; 271: 1913-1918.
64) SURAWICZ CM, MCFARLAND LV, GREENBERG RN, RUBIN
M, FEKETY R, MULLIGAN ME, GARCIA RJ, BRANDMARKER
S, BOWEN K, BORJAL D, ELMER GW. The search for a
better treatment for recurrent Clostridium difficile
disease: use of high-dose vancomycin combined
with Saccharomyces boulardii. Clin Infect Dis
2000; 31: 1012-1017.
65) SURAWICZ CM, ELMER GW, SPEELMAN P, MCFARLAND LV,
CHINN J, VAN BELLE G. Prevention of antibiotic-asso-
ciated diarrhea by Saccharomyces boulardii: A
prospective study. Gastroenterology 1989; 96:
981-988.
66) TUNG JM, DOLOVICH LR, LEE CH. Prevention of
Clostridium difficile infection with Saccharomyces
boulardii: a systematic review. Can J Gastroen-
terol 2009; 23: 817-821.
67) TEMPE JD, STEIDEL AL, BLEHAUT H, HASSELMANN M, LU-
TUN P, MAURIER F. Prevention of diarrhea adminis-
tering Saccharomyces boulardii during continu-
ous enteral feeding. Sem Hôp 1983; 59: 1409-
1412.
68) SCHLOTTERER M, BERNASCONI P, LEBRETON F, WASSER-
MANN D. Value of Saccharomyces boulardii in the
digestive acceptability of continuous-flow enteral
nutrition in burnt patients. Nutr Clin Metab 1987;
1: 31-34.
69) BLEICHNER G, BLÉHAUT H, MENTEC H, MOYSE D. Sac-
charomyces boulardii prevents diarrhea in critical-
ly ill tube-fed patients. A multicenter, randomized,
double-blind placebocontrolled trial. Intensive
Care Med 1997; 23: 517-523.
70) PLEIN K, HOTZ J. Therapeutic effects of Saccha-
romyces boulardii on mild residual symptoms in a
stable phase of Crohn’s disease with special re-
spect to chronic diarrhea–a pilot study. Z Gas-
troenterol 1993; 31: 129-134.
71) GUSLANDI M, MEZZI G, SORGHI M, TESTONI PA. Sac-
charomyces boulardii in maintenance treatment
of Crohn’s disease. Dig Dis Sci 2000; 45: 1462-
1464.
72) CHOI CH, JO SY, PARK HJ, CHANG SK, BYEON JS,
MYUNG SJ. A Randomized, Double-blind, Placebo-
controlled Multicenter Trial of Saccharomyces
boulardii in Irritable Bowel Syndrome: Effect on
Quality of Life. J Clin Gastroenterol 2011; Feb 4
73) BESIRBELLIOGLU BA, ULCAY A, CAN M, ERDEM H,
TANYUKSEL M, AVCI IY, ARAZ E, PAHSA A. Saccha-
romyces boulardii and infection due to Giardia
lamblia. Scand J Infect Dis 2006; 38: 479-481.
74) SAINT-MARC TH, BLEHAUT H, MUSIAL CH, TOURAINE JL.
AIDS related diarrhea: a double-blind trial of Sac-
charomyces boulardii. Sem Hôp Paris 1995; 71:
735-741.
75) DINLEYICI EC, EREN M, DOGAN N, REYHANIOGLU S,
YARGIC ZA, VANDENPLAS Y. Clinical efficacy of Sac-
charomyces boulardii or metronidazole in sympto-
matic children with Blastocystis hominis infection.
Parasitol Res 2011; 108: 541-545.
76) SZAJEWSKA H, SKÒRKA A, DYLAG M. Meta-analysis:
Saccharomyces boulardii for treating acute diar-
rhoea in children. Aliment Pharmacol Ther 2007;
25: 257-264.
77) GUARINO A, ALBANO F, ASHKENAZI S, GENDREL D,
HOEKSTRA JH, SHAMIR R, SZAJEWSKA H. The
ESPGHAN/ESPID Guidelines for the Manage-
ment of Acute Gastroenteritis in Children in Eu-
rope. J Pediatr Gastroenterol Nutr 2008; 46: S81-
122.
78) GRANDY G, MEDINA M, SORIA R, TERÁN CG, ARAYA M.
Probiotics in the treatment of acute rotavirus diar-
rhoea. A randomized, double-blind, controlled trial
using two different probiotic preparations in Boli-
vian children. BMC Infect Dis 2010; 10: 253.
79) EREN M, DINLEYICI EC, VANDENPLAS Y. Clinical effica-
cy comparison of Saccharomyces boulardii and
yogurt fluid in acute non-bloody diarrhea in chil-
dren: a randomized, controlled, open label study.
Am J Trop Med Hyg 2010; 82: 488-491.
80) VANDENPLAS Y, BRUNSER O, SZAJEWSKA H. Saccha-
romyces boulardii in childhood. Eur J Pediatr
2009; 168: 253-265.
81) BUTS JP, CORTHIER G, DELMEE M. Saccharomyces
boulardii for Clostridium difficile-associated en-
teropathies in infants. J Pediatr Gastroenterol Nu-
tr 1993; 16: 419-425.
82) OOI CY, DILLEY AV, DAY AS . Saccharomyces
boulardii in a child with recurrent Clostridium diffi-
cile. Pediatr Int 2009; 5: 156-158.
83) WHO. The treatment of diarrhea. A manual for
physicians and other senior health workers.
WHO/CAH/03.7 10/03
84) GAON D, GARCIA H, WINTER L, RODRIGUEZ N, QUINTAS
R, GONZALES SN, OLIVER G. Effect of Lactobacillus
strains and Saccharomyces boulardii on persis-
tent diarrhea in children. Medicina 2003; 63: 293-
298.
85) CASTANEDA C, GARCIA E, SANTA CRUZ M, FERNANDEZ
M, MONTERREY P. Effects of Saccharomyces
boulardii in children with chronic diarrhea, espe-
cially cases due to giardiasis. Rev Mex Pueric Pe-
diatr 1995; 2: 12-16.
821
S. boulardii in gastroenterology clinical practice
822
86) GOTTELAND M, POLIAK L, CRUCHET S, BRUNSER O. Ef-
fect of regular ingestion of Saccharomyces
boulardii plus inulin or Lactobacillus acidophilus
LB in children colonized by Helicobacter pylori.
Acta Paediatr 2005; 94: 1747-1751.
87) MOGHADDAM DD, GHADIRIAN E, AZAMI M. Blastocystis
hominis and the evaluation of efficacy of metronida-
zole and trimethoprim/sulfamethoxazole. Parasitol
Res 2005; 96: 273-275.
88) NIGRO L, LAROCCA L, MASSARELLI L, PATAMIA I, MINNITI S,
PALERMO F, CACOPARDO B. A placebo-controlled treat-
ment trial of Blastocystis hominis infection with
metronidazole. J Travel Med 2003; 10: 128-130.
89) DINLEYICI EC, EREN M, DOGAN N, REYHANIOGLU S,
YARGIC ZA, VANDENPLAS Y. Clinical efficacy of Sac-
charomyces boulardii or metronidazole in sympto-
matic children with Blastocystis hominis infection.
Parasitol Res 2011; 108: 541-545.
90) DINLEYICI EC, EREN M, YARGIC ZA, DOGAN N, VANDEN-
PLAS Y. Clinical eff icacy of Saccharomyces
boulardii and metronidazole compared to metron-
idazole alone in children with acute bloody diar-
rhea caused by amebiasis: a prospective, ran-
domized, open label study. Am J Trop Med Hyg
2009; 80: 953-955.
91) PERITI P, TONELLI F. Preclinical and clinical pharma-
cology of biotherapeutic agents: S. boulardii. J
Chemother 2001; 13: 473-493.
92) BLEHAUT H ; MASSOT J, ELMER GW, LEVY RH. Disposi-
tion kinetics of S.boulardii in man and rat. Bio-
pharm Drug Dispos 1989; 10: 353-364.
93) GRAFF S, CHAUMEIL JC, BOY P, LAI-KUEN R, CHARRUEAU
C. Formulations for protecting the probiotic Sac-
charomyces boulardii from degradation in acidic
condition. Biol Pharm Bull 2008; 31: 266-272.
94) HENNEQUIN C, KAUFFMANN-LACROIX C, JOBERT A, VIARD JP,
RICOUR C, JACQUEMIN JL, BERCHE P. Possible role of
catheters in Saccharomyces boulardii fungemia. Eur
J Clin Microbiol Infect Dis 2000; 19: 16-20.
95) HWANG JB, KANG KJ, KANG YN, KIM AS. Probiotic
gastrointestinal allergic reaction caused by Sac-
charomyces boulardii. Ann Allergy Asthma Im-
munol 2009; 103: 87-88.
96) ELMER GW, MOYER KA, VEGA R, SURAWICZ CM, COL-
LIER AC, HOOTON TM, MCFARLAND LV. Evaluation of
Saccharomyces boulardii for patients with HIV-
related chronic diarrhoea and in healthy volun-
teers receiving antifungals. Microb Ther 1995;
25: 23-31.
97) HÉBRARD G, HOFFART V, BEYSSAC E, CARDOT JM, ALRIC
M, SUBIRADE M. Coated whey protein/alginate mi-
croparticles as oral controlled delivery systems
for probiotic yeast. J Microencapsul 2010; 27:
292-302.
98) KLEIN SM, ELMER GW, MCFARLAND LV, SURAWICZ CM,
LEVY RH. Recovery and elimination of the bio-
therapeutic agent, Saccharomyces boulardii, in
healthy human volunteers. Pharm Res 1993; 10:
1615-1619.
99) DALGIC N, SANCAR M, BAYRAKTAR B, PULLU M, HASIM
O. Probiotic, Zinc and LactoseFree Formula in
Children with Rotavirus Diarrhea: Are They Ef-
fective? Pediatr Int 2011; Jan 25 
100) BERNI CANANI R, BUCCIGROSSI V, PASSARIELLO A.
Mechanisms of action of zinc in acute diarrhea.
Curr Opin Gastroenterol 2010; Sep 20
101) THOMPSON-CHAGOYAN OC, VIEITES JM, MALDONADO
J, EDWARDS C, GIL A. Changes in faecal microbio-
ta of infants with cow’s milk protein allergy–a
Spanish prospective case-control 6 month fol-
low-up study. Pediatr Allergy Immunol 2010; 21:
e394-400.
102) DI CAGNO R, RIZZELLO CG, DE ANGELIS M, CASSONE
A, GIULIANI G, BENEDUSI A, LIMITONE A, SURICO RF,
GOBBETTI M. Use of selected sourdough strains of
Lactobacillus for removing gluten and enhancing
the nutritional properties of gluten-free bread. J
Food Prot 2008; 71: 1491-1495.
R. Berni Canani, S. Cucchiara, R. Cuomo, F. Pace, F. Papale
